This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
The Board Meeting to be held on 13/02/2026 Stands Cancelled.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivimed Labs has informed BSE and NSE that its board meeting originally scheduled for 13 February 2026 has been postponed. The meeting was meant to approve the financial results for the third quarter of FY2026. The company has not yet announced a revised date and will communicate it to the stock exchanges later. The trading window for insiders remains closed until 48 hours after the financial results are declared post the rescheduled meeting.
This is a routine procedural update with no financial detail disclosed. Shareholders may face a short delay in receiving Q3 FY2026 numbers, but the postponement itself has no direct bearing on the company's fundamentals or stock price. Investors should watch for the revised meeting date announcement.
| Q3 FY26 | Q3 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹15.99 Cr | ₹36.51 Cr | −56.2% |
| Operating profit | −₹16.55 Cr | −₹6.04 Cr | loss widened |
| Profit after tax | −₹16.55 Cr | −₹5.98 Cr | loss widened |
| EBITDA margin | -68.3% | 2.9% | −71.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.